Company MorphoSys AG Xetra

Equities

MOR

DE0006632003

Biotechnology & Medical Research

Business description: MorphoSys AG

Sales by Activity: MorphoSys AG

Geographical breakdown of sales: MorphoSys AG

Managers: MorphoSys AG

Members of the board: MorphoSys AG

Shareholders: MorphoSys AG

Company details: MorphoSys AG

Other Biotechnology & Medical Research

Sector

Quarterly revenue - Rate of surprise

Income Statement and Estimates

Market Closed - Xetra Other stock markets 11:36:08 2024-08-02 am EDT			5-day change	1st Jan Change
67.25 ^EUR	-0.66%		-.--%	+97.79%

Aug. 29	MorphoSys AG Announces Changes in the Composition of the Supervisory Board	CI
Aug. 29	MorphoSys AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Number of employees: 464

Fiscal Period: December	2019	2020	2021	2022	2023
Partnered Discovery	37.47M	49.07M	-	-	-
Proprietary Development	34.29M	279M	-	-	-

See all business segments

Fiscal Period: December	2019	2020	2021	2022	2023
USA	-	-	-	-	211M
Europe (Excluding Germany)	-	-	-	-	26.79M
Asia	-	-	-	-	8K
USA and Canada	32.29M	319M	156M	249M	-
Germany	145K	-	-	-	-
Europe and Asia	39.32M	8.64M	23.33M	29.34M	-

See all geographic segments

Director	Title	Age	Since
Luisa Ciccarelli CTO	Chief Tech/Sci/R&D Officer	-	21-07-31
Tim Demuth CTO	Chief Tech/Sci/R&D Officer	50	22-09-30
Julia Neugebauer IRC	Investor Relations Contact	-	06-08-31
Ann Merchant PRN	Corporate Officer/Principal	59	17-12-31
Daniel Palmacci PRN	Corporate Officer/Principal	-	20-06-30

See MORPHOSYS AG governance

Manager	Title	Age	Since
Sharon Curran BRD	Director/Board Member	56	19-05-21
Heinrich Moisa BRD	Director/Board Member	-	Jun. 05
Romain Lege BRD	Director/Board Member	-	Jun. 05

Composition of the Board of Directors

Name	Equities	%	Valuation
NOVARTIS AG 51.00 %	19,235,376	51.00 %	1 438 M €
Adage Capital Management LP 5.011 %	1,890,000	5.011 %	141 M €
Norges Bank Investment Management 4.481 %	1,690,137	4.481 %	126 M €
RP Management LLC (Investment Management) 3.546 %	1,337,552	3.546 %	100 M €
Goldman Sachs & Co. LLC (Private Banking) 2.876 %	1,084,624	2.876 %	81 M €

List of MORPHOSYS AG shareholders

MorphoSys AG

Semmelweisstrasse 7

82152, Planegg

+49 89 899 27 0

http://www.morphosys.de

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
LONZA GROUP AG	-2.07%	-1.46%	+8.44%	-28.35%	47.07B
IQVIA HOLDINGS INC.	+0.25%	+2.03%	+13.35%	-6.38%	43.64B
ALNYLAM PHARMACEUTICALS, INC.	+1.51%	+7.12%	+48.36%	+44.19%	34.71B
CELLTRION, INC.	-0.20%	-0.31%	+33.24%	-24.84%	30.52B
MODERNA, INC.	+4.08%	-9.20%	-37.18%	-83.26%	26.59B
ICON PUBLIC LIMITED COMPANY	-1.03%	+4.30%	+11.78%	+9.08%	24.48B
UNITED THERAPEUTICS CORPORATION	+0.01%	+0.75%	+56.66%	+72.44%	15.35B
BIO-TECHNE CORPORATION	+0.70%	+2.03%	+2.21%	-43.65%	11.86B
MEDPACE HOLDINGS, INC.	-0.57%	+8.19%	+26.67%	+90.65%	11.03B
Average	+0.30%	+1.38%	+18.17%	+3.32%	27.25B
Weighted average by Cap.	+0.18%	+1.20%	+16.98%	-5.03%

See all sector performances

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

More financial data